A phase I trial of docetaxel and 5-day continuous infusion of 5-fluorouracil in patients with advanced or recurrent breast cancer
| Autor: | Iki Adachi, Tomoko Ohtsu, Y. Omuro, M. Narabayashi, Tetsuo Taguchi, Noriyuki Katsumata, H. Fujii, K. Itoh, D. F. Ying, Tadahiko Igarashi, Masahiko Ando, Yasutsuna Sasaki, Takashi Watanabe, H. Wakita, Y. Tokue |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Adult
Cancer Research medicine.medical_specialty Paclitaxel medicine.medical_treatment Urology Breast Neoplasms Docetaxel Neutropenia Antineoplastic Combined Chemotherapy Protocols Humans Medicine Adverse effect Aged Chemotherapy business.industry Middle Aged medicine.disease Regimen Oncology Fluorouracil Anesthesia Toxicity Female Taxoids Neoplasm Recurrence Local business Perfusion Research Article medicine.drug |
| Zdroj: | British Journal of Cancer |
| ISSN: | 1532-1827 0007-0920 |
| DOI: | 10.1038/bjc.1998.321 |
| Popis: | To determine the maximum-tolerated doses (MTDs), the dose-limiting toxicities (DLTs) and the recommended doses for further trials of docetaxel in combination with a 5-day continuous infusion of 5-fluorouracil (5-FU) in advanced or recurrent breast cancer patients who had been treated previously with at least one chemotherapeutic regimen, patients were treated with docetaxel as a 1-h infusion on day 1 followed by 5-FU as a continuous infusion on days 1 through 5 every 3-4 weeks. Three or six patients were assessed at the following escalating dose levels of docetaxel/5-FU per day: 40/150, 40/300, 50/300, 50/500 and 60/500 mg m(-2). Nineteen patients entered this trial, of whom 18 could be assessed for adverse event and therapeutic efficacy. The DLTs were neutropenia and diarrhoea. The MTDs were 60 mg m(-2) of docetaxel on day 1 and 500 mg m(-2) per day of 5-day continuous infusion of 5-FU. One of 18 patients achieved a complete response and eight achieved partial response (over all response rate: 50%). The recommended doses of docetaxel and 5-day continuous infusion of 5-FU for a phase II trial are 50 mg m(-2) and 500 mg m(-2) per day every 3 or 4 weeks. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|